BeOne Research Collaboration Campaign
Enhancing Understanding and Treatment for B Cell Lymphoma
The BeOne Research Collaboration Campaign aims to advance scientific research and innovation on diseases with high unmet medical needs through global collaboration among academia, hospitals and BeOne Medicines. This year, our focus is on B cell lymphoma research in the preclinical setting.
General Introduction
BeOne will accept research proposals from June 16 – July 15, 2025. Each accepted collaboration will be for a two-year period, and a dedicated scientific liaison will be assigned to each accepted proposal to help manage operational activities and serve as the BeOne point of contact.
Proposals can access the following BeOne resources. The applicants may select one or both options:
-
Funding
Funding requests cannot exceed $300,000 USD per proposal over two years. Allocated funding for winning collaboration proposals may vary based on research scope and size and will be aligned to local fair market value.
-
Scientific Expertise
Access to individuals at BeOne who have expertise in disease biology, drug discovery and translational research.
Please see the Application process and timeline section below. All proposals must be submitted in English.
Areas of Interest
We are seeking preclinical collaborations to advance scientific discovery and accelerate therapeutic innovation in B cell lymphoma with high unmet medical needs, with a focus on mechanistic insights, novel targets, and novel drug modality identification. Research interests include:
-
Disease Biology
Investigating the mechanistic contributions of lymphoma-derived signaling factors and stromal cell populations to understand their roles in establishing and maintaining an immunosuppressive microenvironment.
-
Resistance Mechanisms
Conducting fundamental research to delineate the molecular and cellular mechanisms of primary and acquired resistance to existing therapies, particularly T cell engagers and antibody-drug conjugates, and exploring innovative strategies to overcome these resistances.
-
Innovative Modalities
Pioneering innovative therapeutic modalities with next-generation potential, particularly Biologics, such as antibody-drug conjugates, bispecific and trispecific antibodies.
-
Novel Targets
Discovering and validating novel druggable targets across diverse biological axes, including but not limited to oncogenic drivers, tumor suppressors, and signaling pathways.
Proposals that involve any of the following are not eligible:
- Investigate treatment options in human subjects
- Require any patient interventions
- Use identifiable patient data